134 related articles for article (PubMed ID: 30225852)
1. Lime powder regimen supplement alleviates urinary metabolic abnormalities in urolithiasis patients.
Ungjaroenwathana W; Chiramongkolsiri T; Dissayabutra T; Boonla C; Prapunwattana P; Tungsanga K; Tosukhowong P
Nephrology (Carlton); 2019 Aug; 24(8):791-797. PubMed ID: 30225852
[TBL] [Abstract][Full Text] [Related]
2. Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients.
Tosukhowong P; Yachantha C; Sasivongsbhakdi T; Ratchanon S; Chaisawasdi S; Boonla C; Tungsanga K
Urol Res; 2008 Aug; 36(3-4):149-55. PubMed ID: 18560820
[TBL] [Abstract][Full Text] [Related]
3. In vitro anti-lithogenic activity of lime powder regimen (LPR) and the effect of LPR on urinary risk factors for kidney stone formation in healthy volunteers.
Chariyavilaskul P; Poungpairoj P; Chaisawadi S; Boonla C; Dissayabutra T; Prapunwattana P; Tosukhowong P
Urolithiasis; 2015 Apr; 43(2):125-34. PubMed ID: 25588323
[TBL] [Abstract][Full Text] [Related]
4. [Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis].
Kustov AV; Strelnikov AI; Moryganov MA; Airapetyan AO; Smirnov PR; Lyalyakina EV; Toms SR
Urologiia; 2017 Sep; (4):22-26. PubMed ID: 28952687
[TBL] [Abstract][Full Text] [Related]
5. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
6. Is magnesium a marker of disordered mineral metabolism in males with idiopathic recurrent calcium urolithiasis? Observations focussing on fasting magnesiuria and magnesiemia, protein and other substances in urine and plasma.
Schmiedl A; Schwille PO
Magnes Res; 2003 Sep; 16(3):192-205. PubMed ID: 14596324
[TBL] [Abstract][Full Text] [Related]
7. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein.
Schwille PO; Schmiedl A; Manoharan M
Clin Chem Lab Med; 2004 Mar; 42(3):283-93. PubMed ID: 15080561
[TBL] [Abstract][Full Text] [Related]
8. Lime powder treatment reduces urinary excretion of total protein and transferrin but increases uromodulin excretion in patients with urolithiasis.
Tosukhowong P; Kulpradit P; Chaiyarit S; Ungjareonwattana W; Kalpongnukul N; Ratchanon S; Thongboonkerd V
Urolithiasis; 2018 Jun; 46(3):257-264. PubMed ID: 28585182
[TBL] [Abstract][Full Text] [Related]
9. [Antioxidative activity and clinical efficiency of dietary supplements Nefradoz for treatment of recurrent calcium oxalate urolithiasis].
Kamalov AA; Okhobotov DA; Proskurnina EV; Sozarukova MM; Nizov AN
Urologiia; 2018 Dec; (6):52-59. PubMed ID: 30742378
[TBL] [Abstract][Full Text] [Related]
10. Is idiopathic recurrent calcium urolithiasis in males a cellular disease? Laboratory findings in plasma, urine and erythrocytes, emphasizing the absence and presence of stones, oxidative and mineral metabolism: an observational study.
Schwille PO; Manoharan M; Schmiedl A
Clin Chem Lab Med; 2005; 43(6):590-600. PubMed ID: 16006254
[TBL] [Abstract][Full Text] [Related]
11. Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients.
Herrmann U; Schwille PO; Schwarzlaender H; Berger I; Hoffmann G
Urol Res; 1992; 20(5):347-53. PubMed ID: 1455567
[TBL] [Abstract][Full Text] [Related]
12. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic recurrent calcium urolithiasis (IRCU): an acid meal challenge uncovers inappropriate pH of postprandial, fasting and daily urine: a cross-sectional study of male patients providing insight into post- and pre-load urinary stone substances, crystallization risk, presence of stones, renal transport and systemic metabolic factors.
Schwille PO; Wipplinger J
Eur J Med Res; 2008 Jul; 13(7):332-42. PubMed ID: 18700191
[TBL] [Abstract][Full Text] [Related]
14. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate.
DeFoor WR; Jackson E; Minevich E; Caillat A; Reddy P; Sheldon C; Asplin J
Urology; 2010 Jul; 76(1):242-5. PubMed ID: 20110113
[TBL] [Abstract][Full Text] [Related]
15. [DIAGNOSIS OF METABOLIC DISORDERS AND METAPHYLAXIS OF RECURRENT CALCIUM OXALATE UROLITHIASIS].
Kustov AV; Strelnikov AL; Airapetyan AO; Moryganov MA; Zhuravleva NI
Urologiia; 2015; (5):86-8. PubMed ID: 26859947
[TBL] [Abstract][Full Text] [Related]
16. Lime juice as a dietary alternative to mist potassium citrate for urine alkalinisation: A prospective, cross-over clinical trial.
Sivananthan K; Nagappan P; Md Mansor M; Abdullah U; Azman A
Malays Fam Physician; 2023; 18():5. PubMed ID: 36992952
[TBL] [Abstract][Full Text] [Related]
17. [Urinary citrate excretion in children with calcium urolithiasis].
Sikora P; Bieniaś B; Majewski M; Borzecka H; Wawrzyszuk M; Zajaczkowska M
Przegl Lek; 2006; 63 Suppl 3():134-6. PubMed ID: 16898511
[TBL] [Abstract][Full Text] [Related]
18. Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers.
Fuselier HA; Moore K; Lindberg J; Husserl FE; Cole FE; Kok DJ; Whitehead D; Galliano DJ; Erwin DT
Urology; 1998 Dec; 52(6):988-94. PubMed ID: 9836542
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics of urolithiasis with stone analysis conducted over a 26-year period].
Okuyama M; Yamaguchi S; Kita M; Kato Y; Hashimoto H; Kakizaki H; Wada N; Fujisawa M; Niibori D
Nihon Hinyokika Gakkai Zasshi; 2007 Jan; 98(1):9-16. PubMed ID: 17302289
[TBL] [Abstract][Full Text] [Related]
20. Metabolic assessment of recurrent and first renal calcium oxalate stone formers.
Çakıroğlu B; Eyyupoğlu E; Hazar AI; Uyanik BS; Nuhoğlu B
Arch Ital Urol Androl; 2016 Jul; 88(2):101-5. PubMed ID: 27377084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
